Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediatric and Adolescent Subjects (Aged 4 to 16 Years) With an Acute Exacerbation of Asthma
Conditions
Interventions
fluticasone propionate inhalation solution
oral prednisone
+3 more
Locations
11
China
GSK Investigational Site
Changsha, Hunan, China
GSK Investigational Site
Yanji, Jilin, China
GSK Investigational Site
Shenyang, Liaoning, China
GSK Investigational Site
Wenzhou, Zhejiang, China
GSK Investigational Site
Beijing, China
GSK Investigational Site
Beijing, China
Start Date
November 12, 2012
Primary Completion Date
June 1, 2013
Completion Date
June 21, 2013
Last Updated
June 20, 2018
NCT02327897
NCT07486401
NCT07219173
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions